| A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate ME Weinblatt, JM Kremer, AD Bankhurst, KJ Bulpitt, RM Fleischmann, ... New England Journal of Medicine 340 (4), 253-259, 1999 | 2713 | 1999 |
| A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis JM Bathon, RW Martin, RM Fleischmann, JR Tesser, MH Schiff, ... New England Journal of Medicine 343 (22), 1586-1593, 2000 | 2408 | 2000 |
| Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein LW Moreland, SW Baumgartner, MH Schiff, EA Tindall, RM Fleischmann, ... New England Journal of Medicine 337 (3), 141-147, 1997 | 2094 | 1997 |
| Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial LW Moreland, MH Schiff, SW Baumgartner, EA Tindall, RM Fleischmann, ... Annals of internal medicine 130 (6), 478-486, 1999 | 1951 | 1999 |
| The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double‐blind, placebo … P Emery, R Fleischmann, A Filipowicz‐Sosnowska, J Schechtman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 1464 | 2006 |
| Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis R Fleischmann, J Kremer, J Cush, H Schulze-Koops, CA Connell, ... New England Journal of Medicine 367 (6), 495-507, 2012 | 1083 | 2012 |
| Tofacitinib or adalimumab versus placebo in rheumatoid arthritis RF Van Vollenhoven, R Fleischmann, S Cohen, EB Lee, ... New England Journal of Medicine 367 (6), 508-519, 2012 | 1082 | 2012 |
| Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate V Strand, S Cohen, M Schiff, A Weaver, R Fleischmann, G Cannon, R Fox, ... Archives of internal medicine 159 (21), 2542-2550, 1999 | 1045 | 1999 |
| Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes MC Genovese, JM Bathon, RW Martin, RM Fleischmann, JR Tesser, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2002 | 991 | 2002 |
| Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial JC Davis Jr, D Van Der Heijde, J Braun, M Dougados, J Cush, DO Clegg, ... Arthritis & Rheumatism 48 (11), 3230-3236, 2003 | 987 | 2003 |
| Tofacitinib versus methotrexate in rheumatoid arthritis EB Lee, R Fleischmann, S Hall, B Wilkinson, JD Bradley, D Gruben, ... New England Journal of Medicine 370 (25), 2377-2386, 2014 | 827 | 2014 |
| Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis SR Ytterberg, DL Bhatt, TR Mikuls, GG Koch, R Fleischmann, JL Rivas, ... New England Journal of Medicine 386 (4), 316-326, 2022 | 803 | 2022 |
| Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis … DE Furst, MH Schiff, RM Fleischmann, V Strand, CA Birbara, ... The Journal of Rheumatology 30 (12), 2563-2571, 2003 | 716 | 2003 |
| Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study D Van Der Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, ... Arthritis & Rheumatism 65 (3), 559-570, 2013 | 631 | 2013 |
| Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) PJ Mease, R Fleischmann, AA Deodhar, J Wollenhaupt, M Khraishi, ... Annals of the rheumatic diseases 73 (1), 48-55, 2014 | 582 | 2014 |
| Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis … P Emery, RM Fleischmann, LW Moreland, EC Hsia, I Strusberg, P Durez, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009 | 547 | 2009 |
| Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double‐blind treatment phase of a … JM Kremer, R Blanco, M Brzosko, R Burgos‐Vargas, AM Halland, ... Arthritis & Rheumatism 63 (3), 609-621, 2011 | 540 | 2011 |
| Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial J Kremer, ZG Li, S Hall, R Fleischmann, M Genovese, E Martin-Mola, ... Annals of internal medicine 159 (4), 253-261, 2013 | 504 | 2013 |
| Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase … R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots, Z Luo, R DeMasi, ... The Lancet 390 (10093), 457-468, 2017 | 496 | 2017 |
| Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo‐controlled … RM Fleischmann, J Schechtman, R Bennett, ML Handel, GR Burmester, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2003 | 467 | 2003 |
